Please wait while the formulary information is being retrieved.
BESREMI (ropeginterferon alfa-2b-njft)
- Polycythemia vera
500 mcg/mL subcutaneous syringe
- Dosage information is not available
Default screening record
- Inject 500 mcg by subcutaneous route every 2 weeks
- Inject 500 mcg by subcutaneous route every 4 weeks
- Inject 450 mcg by subcutaneous route every 2 weeks
- Inject 400 mcg by subcutaneous route every 2 weeks
- Inject 350 mcg by subcutaneous route every 2 weeks
- Inject 300 mcg by subcutaneous route every 2 weeks
- Inject 250 mcg by subcutaneous route every 2 weeks
- Inject 200 mcg by subcutaneous route every 2 weeks
- Inject 150 mcg by subcutaneous route every 2 weeks
- Inject 100 mcg by subcutaneous route every 2 weeks
- Inject 50 mcg by subcutaneous route every 2 weeks
- Inject 450 mcg by subcutaneous route every 4 weeks
- Inject 400 mcg by subcutaneous route every 4 weeks
- Inject 350 mcg by subcutaneous route every 4 weeks
- Inject 300 mcg by subcutaneous route every 4 weeks
- Inject 250 mcg by subcutaneous route every 4 weeks
- Inject 200 mcg by subcutaneous route every 4 weeks
- Inject 150 mcg by subcutaneous route every 4 weeks
- Inject 100 mcg by subcutaneous route every 4 weeks
- Inject 50 mcg by subcutaneous route every 4 weeks
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- clozapine
- Clozaril
- deferiprone
- Droxia
- Fazaclo
- Ferriprox
- Hydrea
- hydroxyurea
- Versacloz
Severe
Moderate
- erlotinib
- Tarceva
- Acute pancreatitis
- Aplastic anemia
- Autoimmune hepatitis
- Child-pugh class B hepatic impairment
- Child-pugh class C hepatic impairment
- Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min
- Chronic kidney disease stage 5 (failure) GFr<15 ml/min
- Hemorrhagic colitis
- Hepatic failure
- Ischemic colitis
- Lactation
Contraindicated
- Cerebrovascular accident
- Colitis
- Depression
- Diabetic retinopathy
- Hypertensive retinopathy
- Kidney disease with likely reduction in GFR
- Pregnancy
- Psychiatric disorder
- Retinal thrombosis
- Severe anemia
- Severe hepatic disease
- Severe infection
- Severe neutropenic disorder
- Severe thrombocytopenia
- Suicidal ideation
Severe
Moderate
- Autoimmune disease
- Diabetes mellitus
- Hyperthyroidism
- Hypoglycemic disorder
- Hypothyroidism
- Peripheral neuropathy
- Pulmonary disease
BESREMI (ropeginterferon alfa-2b-njft)
- Polycythemia vera
- Abnormal hepatic function tests
- Increased alanine transaminase
- Increased aspartate transaminase
- Alopecia
- Anorexia
- Arthralgia
- Chills
- Diarrhea
- Dizziness
- Fatigue
- Fever
- Flu-like symptoms
- Headache disorder
- Injection site sequelae
- Irritability
- Musculoskeletal pain
- Nausea
- Pharyngitis
- Pruritus of skin
- Skin rash
More Frequent
Severe
Less Severe
- Anemia
- Depression
- Dyspnea
- Hyperbilirubinemia
- Hypertension
- Hyperthyroidism
- Hypothyroidism
- Leukopenia
- Thrombocytopenic disorder
- Acneiform eruption
- Cataracts
- Dry eye
- Edema
- Erythema
- Hyperlipidemia
- Mood changes
- Muscle spasm
- Myalgia
- Sleep disorder
- Upper respiratory infection
- Urinary tract infection
- Vertigo
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute myocardial infarction
- Aggressive behavior
- Anaphylaxis
- Angioedema
- Atrial fibrillation
- Bronchospastic pulmonary disease
- Cardiomyopathy
- Diabetes mellitus
- Drug-induced psychosis
- Hypersensitivity drug reaction
- Hypertriglyceridemia
- Infection
- Interstitial nephritis
- Interstitial pneumonitis
- Kidney disease with reduction in GFR
- Manic disorder
- Myocardial ischemia
- Neutropenic disorder
- Pancreatitis
- Pneumonia
- Pulmonary hypertension
- Pulmonary infiltrates
- Retinal detachment
- Retinal disorder
- Retinal hemorrhage
- Retinal vascular occlusion
- Sarcoidosis
- Suicidal
- Suicidal ideation
- Thyroiditis
- Ulcerative colitis
- Urticaria
- Vision loss
Less Severe
- Bronchiolitis
- Dry skin
- General weakness
- Hyperhidrosis
- Hyperkeratosis
- Malaise
- Migraine
- Psoriasis
- Tooth disorder
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Ropeginterferon alfa-2b-njft
Safety and effectiveness not established in pediatric patients < 18 years.
- 1 Day – 18 Years
- Safety and effectiveness not established in pediatric patients < 18 years.
Ropeginterferon Alfa-2B-njft
- Severity Level:
D
- Additional Notes: Insuff data avail; based on drug pharmacology developmental toxicity is possible
Contraindicated
Ropeginterferon Alfa-2B-njft
Mfg rec to avoid breastfeeding during tx and for 8 weeks after last dose
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Mfg rec to avoid breastfeeding during tx and for 8 weeks after last dose |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- This medication may rarely cause or worsen some serious medical conditions, including mental/mood problems (such as depression), autoimmune conditions (such as lupus, rheumatoid arthritis), blood vessel problems (such as heart disease), or infections. Careful monitoring by your doctor may decrease your risk. Tell your doctor right away if you develop any serious symptoms or side effects (see Side Effects section). Some side effects may go away or lessen after stopping treatment with this medication.
| Polycythemia vera | |
| D45 | Polycythemia vera |
| 0-9 | A-Z |
|---|---|
| D45 | Polycythemia vera |
Formulary Reference Tool